PUBLISHER: Grand View Research | PRODUCT CODE: 2112253
PUBLISHER: Grand View Research | PRODUCT CODE: 2112253
The global pharmaceutical contract manufacturing and research services market size was valued at USD 283.1 billion in 2025 and is projected to grow from USD 303.8 billion in 2026 to USD 472.1 billion by 2033, at a CAGR of 6.5% from 2026 to 2033. Asia Pacific dominated the market, accounting for the largest share of 42.3% in 2025. The pharmaceutical contract manufacturing and research services industry is anticipated to grow over the forecast period owing to increasing pharmaceutical and biotechnology outsourcing, rising research and development activities for biologics, biosimilars, and specialty drugs, growing demand for cost-efficient and flexible manufacturing, expanding clinical trial pipeline, and increasing investments in advanced manufacturing technologies and integrated CDMO and CRO capabilities.
The market growth is further supported by the need to reduce development timelines, manage complex regulatory requirements, and access specialized technical expertise without large capital investments. The growing focus on end-to-end outsourcing across drug discovery, development, and commercial manufacturing is strengthening demand for contract manufacturing and research service providers.
The increasing outsourcing of pharmaceutical development and manufacturing remains one of the primary growth drivers for the market. Pharmaceutical and biotechnology companies are increasingly partnering with contract service providers to reduce infrastructure costs, improve operational flexibility, and accelerate product development timelines. The growing complexity of biologics, cell and gene therapies, highly potent compounds, and personalized medicines has further increased the need for specialized manufacturing and research capabilities. The integrated service model offered by contract organizations enables sponsors to manage development and commercialization through a single partner while maintaining regulatory compliance and improving operational efficiency.
The expansion of manufacturing capacity and specialized capabilities across leading service providers is further supporting market growth. Companies continue to invest in advanced production technologies and high-value manufacturing infrastructure to address increasing outsourcing demand. For instance, in November 2024, Lonza announced the expansion of its bioconjugation capabilities at its Visp, Switzerland, facility by adding two 1,200 L manufacturing suites to support growing demand for complex therapeutics. The investment is expected to strengthen commercial manufacturing capacity for advanced pharmaceutical products and enhance integrated development and manufacturing services offered to global pharmaceutical and biotechnology companies. Market growth is moderated by stringent regulatory compliance requirements, high capital investment for advanced manufacturing facilities, and pricing pressure across outsourcing contracts. The increasing demand for biologics, specialty therapeutics, integrated development services, and the expansion of pharmaceutical outsourcing across emerging markets are expected to create significant opportunities for contract manufacturing and research service providers over the coming years. Overall, the increasing preference for outsourcing, expanding drug development pipelines, and continuous investments in specialized research and manufacturing capabilities are expected to support the long-term growth of the pharmaceutical contract manufacturing and research services market.
Global Pharmaceutical Contract Manufacturing And Research Services Market Report Segmentation
This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharmaceutical contract manufacturing and research services market report based on service and region: